Dong A Pharmaceutical Research Institute, Yongin 130-708, Korea.
J Clin Biochem Nutr. 2008 May;42(3):204-14. doi: 10.3164/jcbn.2008030.
Quality of ulcer healing (QOUH) is defined as ideal ulcer healing featuring with the fine granular ulcer scar, high functional restoration and the resistance to recurrence. This study was designed to compare the rates of QOUH achievement in rat gastric ulcer model between acid suppressant treated group and gastroprotectant treated group accompanied with elucidations of molecular mechanisms. Serosal injection of acetic acids for generating gastric ulcer and intraperitoneal (ip) injection of recombinant interleukin 1-beta (IL-1beta) for recurring healed ulcer was done in SD rats. The 72 rats were divided into three groups according to treatment as follows; Group I, no further treatment, Group II, 8 weeks treatment of omeprazole, and Group III, 8 weeks of gastroprotectant treatment. IL-1beta was administered for ulcer recurrence after 28 weeks of acetic acid injection. At four weeks after gastric ulcerogenesis, 58.3% (7/12) of active gastric ulcer were converted to healing stage in Group III, but 16.7% (2/12) in Group II and none in Group I, for which significant levels of epidermal growth factor, mucin, and pS2/trefoil peptide1 were contributive to these accelerated healings of Group III. ip injections of rIL-1beta (200 microg/kg) at 28 weeks after acetic acid injection led to 100% of ulcer recurrence in Group I and 75.0% in Group II, but only 16.7% of Group III rats showed ulcer recurrence. Significantly attenuated levels of inflammatory cytokines including IL-2, transforming growth factor-alpha (TNF-alpha), cyclooxygenase-2 (COX-2), nitrotyrosine were responsible for the resistance to ulcer recurrence in Group III. Conclusively, gastroprotectant might be prerequisite in order to achieve ideal QOUH through significant inductions of remodeling.
溃疡愈合质量(QOUH)被定义为理想的溃疡愈合,具有精细的颗粒状溃疡疤痕、高功能恢复和抵抗复发的特点。本研究旨在比较抑酸剂治疗组和胃保护剂治疗组在大鼠胃溃疡模型中达到 QOUH 的比率,并阐明其分子机制。通过向 SD 大鼠腹膜内注射重组白细胞介素 1-β(IL-1β)以促进溃疡复发,从而在胃黏膜表面注射醋酸来产生胃溃疡。根据治疗方法,将 72 只大鼠分为三组:I 组,不进一步治疗;II 组,奥美拉唑治疗 8 周;III 组,胃保护剂治疗 8 周。在醋酸注射 28 周后给予 IL-1β 以促进溃疡复发。在胃溃疡形成后四周,III 组有 58.3%(12/20)的活动性胃溃疡转化为愈合期,而 II 组有 16.7%(12/72),I 组则没有,这归因于表皮生长因子、粘蛋白和 pS2/trefoil 肽 1 的显著水平,这些因素促进了 III 组的愈合。在醋酸注射 28 周后腹膜内注射 rIL-1β(200μg/kg)导致 I 组 100%的溃疡复发,II 组 75.0%的溃疡复发,但 III 组只有 16.7%的大鼠出现溃疡复发。炎症细胞因子包括白细胞介素 2、转化生长因子-α(TNF-α)、环氧化酶-2(COX-2)和硝基酪氨酸的水平显著降低,这是 III 组抵抗溃疡复发的原因。总之,胃保护剂可能是通过显著诱导重塑来实现理想的 QOUH 的前提。